Breaking News Instant updates and real-time market news.

AMGN

Amgen

$171.29

1.67 (0.98%)

, GILD

Gilead

$66.51

-0.01 (-0.02%)

17:30
05/22/19
05/22
17:30
05/22/19
17:30

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead

Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."

AMGN

Amgen

$171.29

1.67 (0.98%)

GILD

Gilead

$66.51

-0.01 (-0.02%)

ALXN

Alexion

$127.47

-1.33 (-1.03%)

VRTX

Vertex

$172.37

3.22 (1.90%)

BMRN

BioMarin

$87.80

0.33 (0.38%)

BIIB

Biogen

$234.98

2.04 (0.88%)

REGN

Regeneron

$320.00

10.19 (3.29%)

  • 29

    May

  • 31

    May

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 28

    Jun

AMGN Amgen
$171.29

1.67 (0.98%)

05/22/19
SBSH
05/22/19
UPGRADE
SBSH
Buy
Amgen upgraded to Buy from Neutral at Citi
05/20/19
FBCO
05/20/19
INITIATION
Target $208
FBCO
Outperform
Amgen initiated with an Outperform at Credit Suisse
Credit Suisse analyst Evan Seigerman initiated Amgen with an Outperform rating and a price target of $208, saying the stock is "attractive" relative to its peers because of its "underappreciated" biosimilars assets that may offset the expected revenue decline in its core business. The analyst is also positive on Amgen's promising pipeline that includes oncology and immunology assets along with its discounted valuation, noting that the stock is currently trading at 12.1-times expected forward earnings vs. 17.7-times for the S&P500 and 14.4-times or more for its major pharma peers.
05/16/19
COWN
05/16/19
NO CHANGE
COWN
Outperform
Amgen early data for AMG 510 'looks strong,' says Cowen
Cowen analyst Yaron Werber said the initial data in ASCO abstract for Amgen's AMG 510 "looks strong" in lung cancer patients and was better than he anticipated. The data, while still early, suggest AMG 510 is a promising therapy for a "sizable" $2B-$2.5B market, Werber tells investors. He maintains an Outperform rating on Amgen shares.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
GILD Gilead
$66.51

-0.01 (-0.02%)

05/20/19
FBCO
05/20/19
INITIATION
Target $70
FBCO
Neutral
Gilead initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Gilead Sciences with a Neutral rating and $70 price target. The does not see "outsized growth" in the company's base HIV business that would drive significant upside to earnings projections. He admits, however, that a new strategic vision or acquisition could lead to multiplier expansion.
05/13/19
JEFF
05/13/19
NO CHANGE
Target $95
JEFF
Buy
Gilead shares reflect 'undue bearish outlook,' says Jefferies
Gilead Sciences (GILD) is trading at a 10 times price-to-earnings multiple, which reflects an "undue bearish outlook," Jefferies analyst Michael Yee tells investors in a research note. He thinks the company's base HIV business growing to 2025 and then eroding is worth $60-$65 per share, and the rest of business -- HCV, filgotinib, Yescarta -- is worth $15-$20 per share. This implies the stock should be at $80-$85, says Yee. A bear case on the HIV business is $35-$40 per share, which assumes a full cliff post 2025 or GlaxoSmithKline (GSK) taking "massive" share with doublets and long-acting, adds the analyst. Yee keeps a Buy rating on Gilead with a $95 price target.
05/22/19
SBSH
05/22/19
UPGRADE
SBSH
Buy
Gilead upgraded to Buy from Neutral at Citi
05/10/19
RILY
05/10/19
NO CHANGE
Target $158
RILY
Buy
Intercept added to Alpha Generator list at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani earlier today added Intercept Pharmaceuticals (ICPT) to his firm's Alpha Generator list. The analyst sees "strong" strong fundamentals over next year and a high likelihood of FDA approval in mid-2020. Mamtani lowered his price target for Intercept to $158 from $169 and keeps a Buy rating on the shares. His new target reflects the company's recent capital raise, the removal of removing Gilead (GILD) as near-term competitor with selonsertib's recent failure, and the push out of a European launch from the second half of 2020 to Q1 of 2021.
ALXN Alexion
$127.47

-1.33 (-1.03%)

04/25/19
PIPR
04/25/19
NO CHANGE
Target $180
PIPR
Overweight
Piper remains buyer of Alexion shares to levels approaching $180
Piper Jaffray analyst Christopher Raymond says Alexion Pharmaceuticals reported "another strong quarter" and its seventh consecutive quarterly raise. The commercial story is playing out as hoped, and management is taking a characteristically conservative approach to guidance, Raymond tells investors in a research note. He remains a buyer of the stock to levels approaching $180 and keeps an Overweight rating on the name. Alexion remains the analyst's top large-cap pick. The stock in late day trading is up 4% to $135.30.
05/22/19
WEDB
05/22/19
INITIATION
Target $173
WEDB
Outperform
Alexion initiated with an Outperform at Wedbush
Wedbush analyst Laura Chico started Alexion with an Outperform rating and $173 price target.
04/10/19
RAJA
04/10/19
INITIATION
Target $161
RAJA
Outperform
Alexion resumed with an Outperform at Raymond James
Raymond James analyst Steven Seedhouse resumed coverage of Alexion with an Outperform rating and $161 price target, citing what he sees as good visibility into continued growth as the company works to switch patients from Soliris to Ultomiris and pursues subcutaneous follow-on products to extend "existing, successful franchises." He models upside even without any pipeline contributions, the analyst noted.
04/02/19
PIPR
04/02/19
NO CHANGE
PIPR
Overweight
Piper says AAN meeting should be 'meaningful' for Alexion, Biogen
Piper Jaffray analyst Christopher Raymond reported that the American Academy of Neurology posted emerging science abstract titles this morning, adding that full abstracts are not anticipated until May 3. It appears Phase 3 data on Alexion's (ALXN) Soliris for Neuromyelitis Optica Spectrum Disorder, or NMOSD, will be presented as an emerging science abstract and that data from a Phase 1/2 study of Biogen's (BIIB) BIIB067 in SOD1 mutant ALS patients will also be presented, making the meeting potentially "meaningful" for both. Raymond keeps Overweight ratings on Alexion and Biogen.
VRTX Vertex
$172.37

3.22 (1.90%)

05/20/19
FBCO
05/20/19
INITIATION
Target $209
FBCO
Outperform
Vertex initiated with an Outperform at Credit Suisse
Credit Suisse analyst Evan Seigerman started Vertex Pharmaceuticals with an Outperform rating and $209 price target. The analyst also names Vertex his top large-cap pick in U.S. Biotechnology. The company has a "differentiated growth profile" that should not only drive near-term cash flows, but also allow reinvestment in the business to support longer-term growth, Seigerman tells investors in a research note. He sees continued commercial execution, pipeline updates and guidance updates supporting the shares relative to peers.
05/15/19
PIPR
05/15/19
NO CHANGE
Target $217
PIPR
Overweight
Piper Jaffray bullish on Vertex following protein degradation partnership
Piper Jaffray analyst Edward Tenthoff notes that Vertex has partnered with private protein degradation company Kymera for $70M upfront and up to $1B in potential milestones. Vertex is diversifying outside of Cystic Fibrosis in order to generate the next leg of long-term growth, he notes. The analyst is confident in the FDA and EMA approval of Vertex's game-changing TripleRx in 2020 following NDA filing in Q3 and OUS by year end 2019. Tenthoff projects total CF sales will grow from $3.52B this year to $4.51B in 2020 with TripleRx launch. He reiterates an Overweight rating and $217 price target on the shares.
04/11/19
EVER
04/11/19
INITIATION
Target $183
EVER
In Line
Vertex initiated with an In Line at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Vertex with an In-Line rating and a price target of $183. The analyst says the company has "great science, execution, and management", but its multiple is the highest relative to its peers and appears to be "priced to perfection". Mehrotra adds that the debate around EU pricing will intensify, becoming a "bigger and longer headwind".
04/16/19
PIPR
04/16/19
NO CHANGE
Target $75
PIPR
Overweight
Piper reiterates $75 target for Crispr after CTX001 gets Fast Track
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics after the company and partner Vertex (VRTX) announced Fast Track Designation for CTX001 to treat transfusion-dependent beta thalassemia. The analyst believes Crispr's ex vivo approach and biological rational of targeting fetal hemoglobin "de-risk and differentiate" CTX001 from other gene editing players. And he continues to think that first-in-man CTX001 data this year "will serve as an important driver" for Crispr and the gene editing field. Tenthoff says Crispr Therapeutics remains a top for 2019.
BMRN BioMarin
$87.80

0.33 (0.38%)

05/22/19
JPMS
05/22/19
NO CHANGE
Target $133
JPMS
Overweight
JPMorgan likes BioMarin risk/reward into gene therapy update
JPMorgan analyst Cory Kasimov likes the risk/reward on shares of BioMarin Pharmaceuticals into the three-year update for the company's valrox gene therapy program in hemophilia A, which is expected by June 7. The analyst expects valrox "to continue to look like an approvable and commercially relevant product." However, it can also be argued that BioMarin is undervalued at these levels even without valrox, Kasimov tells investors in a research note. Following a sum-of-the-parts analysis, the analyst believes BioMarin "represents a compelling opportunity at this time." He keeps an Overweight rating on the shares with a $133 price target.
05/02/19
JEFF
05/02/19
NO CHANGE
Target $12
JEFF
Buy
Valrox could become BioMarin's largest product, says Jefferies
BioMarin is set to report topline three-year Phase 2 data for hemophilia A gene therapy valrox by June 7, including clotting factor VIII levels, annualized bleeding rate, and factor VIII usage, Jefferies analyst Eun Yang tells investors in a research note. The analyst estimates potential valrox market size at $12B in the U.S. and $10B in Europe. As such, valrox, if efficacy is durable, has the potential to be the largest product for BioMarin, says the analyst. After surveying 26 U.S. hematologists, Yang believes doctors are focused more on the clinically relevant bleeding rate for valrox utilization, in line with BioMarin's position, versus the Street's focus on factor VIII levels. If valrox is approved and 10%-30% of patients receive valrox thru 2023, the analyst sees 11%-30% upside to her current price target of $125 for BioMarin shares. She keeps a Buy rating on the name.
05/16/19
CANT
05/16/19
NO CHANGE
Target $131
CANT
Overweight
BioMarin rally yesterday 'could be just the beginning,' says Cantor Fitzgerald
The 8% rally yesterday in shares of BioMarin as the company presented at a sell-side conference "could be just the beginning of a major swing in sentiment" if the valrox update before June 7 is positive, Cantor Fitzgerald analyst Eliana Merle tells investors in a research note. The analyst thinks BioMarin is "poised for a large move" this year if valrox is positive given skepticism about the drug's long-term durability. She sees a "highly favorable" risk/reward into "many potentially transformative updates" over 2019, with upside to $150 per share versus downside to $60-$70 per share. Merle reiterates an Overweight rating on BioMarin with a $131 price target.
05/13/19
JEFF
05/13/19
NO CHANGE
Target $125
JEFF
Buy
BioMarin risk/reward favorable into valrox data, says Jefferies
Jefferies analyst Eun Yang sees a favorable risk/reward on BioMarin shares following her physician poll on valrox. The analyst sees a "reasonable likelihood" that the three-year follow-up data, to be reported by June 7, will show durable efficacy and FVIII expression similar to that at year two. However, the stock's current valuation reflects little such expectation, Yang tells investors in a research note. She keeps a Buy rating on BioMarin with a $125 price target.
BIIB Biogen
$234.98

2.04 (0.88%)

05/09/19
LEHM
05/09/19
NO CHANGE
Target $245
LEHM
Equal Weight
Barclays cuts Biogen target to $245 on reduced Spinraza estimates
Barclays analyst Geoff Meacham lowered his price target for Biogen (BIIB) to $245 from $250 citing growing uncertainty in spinal muscular atrophy. Concerns over Spinraza in spinal muscular atrophy have intensified with the impending launch of Novartis' (NVS) gene therapy Zolgensma and Roche (RHHBY)/PTC's (PTCT) oral risdiplam, Meacham tells investors in a research note. The analyst says his feedback from key opinion leaders was "direct and unequivocal," with the leaders predicting "robust uptake" of both Zolgensma and risdiplam given signs of improved efficacy. This was at the expense of Spinraza driven by the clinical burden of intrathecal injections, says Meacham. On the basis of this feedback, he lowered his longer-term Spinraza outlook by ~$150M per year. The analyst now forecasts sales of $2.0B in 2019, declining to $1.7B in 2023. He keeps an Equal Weight rating on Biogen.
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/22/19
WEDB
05/22/19
INITIATION
Target $231
WEDB
Neutral
Biogen initiated with a Neutral at Wedbush
Wedbush analyst Laura Chico started Biogen with a Neutral rating and $231 price target.
05/20/19
FBCO
05/20/19
INITIATION
FBCO
Underperform
Biogen initiated with an Underperform at Credit Suisse
Credit Suisse analyst Evan Seigerman initiated Biogen with an Underperform rating and $198 price target, saying that "life beyond aducanumab will likely remain challenging for Biogen" with the company's core base business "likely to decline in the near term with a weak pipeline that will not likely be able to yield revenue and earnings growth." While Seigerman said that Biogen's MS business is stable, he noted that headwinds are mounting.
REGN Regeneron
$320.00

10.19 (3.29%)

05/16/19
JPMS
05/16/19
NO CHANGE
Target $395
JPMS
Neutral
Regeneron selloff brings improved risk/reward, says JPMorgan
JPMorgan analyst Cory Kasimov keeps a Neutral rating on shares of Regeneron Pharmaceuticals buy says the stock's risk/reward is improved following the recent sharp pullback. The analyst adds that feedback from five doctors supports his above-consensus estimates for Dupixent. Kasimov currently models peak sales north of $7B across atopic dermatitis, asthma, and nasal polyps in the U.S. and Europe, "with everything else left as upside." Every $1B in total Dupixent revenue results in a $20 impact to the stock's fair valuation, the analyst tells investors in a research note titled "Dupi...How Big Is Big?"
05/21/19
PIPR
05/21/19
NO CHANGE
Target $435
PIPR
Overweight
Piper, confident in Street-high Dupixent estimates, says buy Regeneron
Piper Jaffray analyst Christopher Raymond says he's increasingly confident in his Street-high Dupixent estimates following his firm's latest dermatologist survey. The survey indicated "steepening use trends" for Regeneron Pharmaceuticals' Dupixent and a "meaningful inflection" in use for atopic dermatitis, Raymond tells investors in a research note. Further, the feedback suggests that the new adolescent atopic dermatitis label is already driving "meaningful growth as well as continued acceleration," adds the analyst. He recommends buying shares of Regeneron at current levels and keeps an Overweight rating on the name with a $435 price target.
05/20/19
LEHM
05/20/19
NO CHANGE
Target $315
LEHM
Underweight
Barclays still bearish on Regeneron despite 18% drop year-to-date
Barclays analyst Geoff Meacham says that despite the 18% decline of Regeneron Pharmaceuticals shares year-to-date, he remains bearish on the name with an Underweight rating and $315 price target. The analyst cites Eylea concentration risk and the near/long-term competitive threat in wet age-related macular degeneration. Pricing and/or share erosion in wet AMD from brolucizumab or DARPin could yield worse than consensus expectations, Meacham tells investors in a research note.
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.

TODAY'S FREE FLY STORIES

ACM

Aecom

$33.41

-0.035 (-0.10%)

06:58
06/17/19
06/17
06:58
06/17/19
06:58
Earnings
AECOM backs FY19 adjusted EPS view $2.60-$2.90, consensus $2.82 »

AECOM reiterated its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOW

Dow Inc.

$51.12

-1.77 (-3.35%)

06:57
06/17/19
06/17
06:57
06/17/19
06:57
Downgrade
Dow Inc. rating change  »

Dow Inc. cut to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$33.41

-0.035 (-0.10%)

06:56
06/17/19
06/17
06:56
06/17/19
06:56
Hot Stocks
Aecom announces intent to spin off government services business »

AECOM announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$350.23

1.04 (0.30%)

, RTN

Raytheon

$177.38

0.195 (0.11%)

06:56
06/17/19
06/17
06:56
06/17/19
06:56
Periodicals
Lockheed Martin does not see F-35 impact from Raytheon-UTC merger, Reuters says »

Lockheed Martin (LMT) is…

LMT

Lockheed Martin

$350.23

1.04 (0.30%)

RTN

Raytheon

$177.38

0.195 (0.11%)

UTX

United Technologies

$125.30

0.45 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

PRK

Park National

$99.06

-0.04 (-0.04%)

06:54
06/17/19
06/17
06:54
06/17/19
06:54
Initiation
Park National initiated  »

Park National initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEPT

Neptune Wellness

$4.28

0.025 (0.59%)

06:54
06/17/19
06/17
06:54
06/17/19
06:54
Hot Stocks
Neptune Wellness subsidiary announces cannabis extraction capacity increase »

Neptune Wellness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKU

BankUnited

$33.20

-0.03 (-0.09%)

06:52
06/17/19
06/17
06:52
06/17/19
06:52
Hot Stocks
BankUnited names Michael Alford as general counsel »

BankUnited announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$10.24

-0.08 (-0.78%)

06:52
06/17/19
06/17
06:52
06/17/19
06:52
Recommendations
General Electric analyst commentary  »

JPMorgan's Tusa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHT

Ashford Hospitality

$3.65

-0.64 (-14.92%)

06:52
06/17/19
06/17
06:52
06/17/19
06:52
Downgrade
Ashford Hospitality rating change  »

Ashford Hospitality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBY

NovaBay

$1.69

-0.38 (-18.36%)

06:51
06/17/19
06/17
06:51
06/17/19
06:51
Hot Stocks
NovaBay names Justin Hall as CEO, Jason Raleigh as CFO »

NovaBay announces the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTRH

Quarterhill

$1.10

(0.00%)

06:50
06/17/19
06/17
06:50
06/17/19
06:50
Hot Stocks
Quarterhill CFO Shaun McEwan to depart »

Quarterhill and its board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VWAGY

Volkswagen

$0.00

(0.00%)

06:49
06/17/19
06/17
06:49
06/17/19
06:49
Periodicals
Volkswagen's Chattanooga plant workers vote to reject union plans, NYT says »

Results of the vote…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$42.75

0.24 (0.56%)

, ARRY

Array BioPharma

$29.59

0.17 (0.58%)

06:49
06/17/19
06/17
06:49
06/17/19
06:49
Hot Stocks
Pfizer to acquire Array BioPharma for $48.00 per share in cash, or $11.4B »

Pfizer (PFE) and Array…

PFE

Pfizer

$42.75

0.24 (0.56%)

ARRY

Array BioPharma

$29.59

0.17 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 16

    Sep

CIR

Circor

$44.81

-0.12 (-0.27%)

, CR

Crane

$79.66

-1.77 (-2.17%)

06:49
06/17/19
06/17
06:49
06/17/19
06:49
Hot Stocks
Crane commences tender offer to acquire CIRCOR for $45 per share in cash »

Crane Co. (CR) commenced…

CIR

Circor

$44.81

-0.12 (-0.27%)

CR

Crane

$79.66

-1.77 (-2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CJ

C&J Energy Services

$10.73

-0.47 (-4.20%)

, FRAC

Keane Group

$6.99

-0.46 (-6.17%)

06:49
06/17/19
06/17
06:49
06/17/19
06:49
Hot Stocks
C&J Energy Services, Keane Group enter all-stock merger »

C&J Energy Services…

CJ

C&J Energy Services

$10.73

-0.47 (-4.20%)

FRAC

Keane Group

$6.99

-0.46 (-6.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CR

Crane

$79.66

-1.77 (-2.17%)

, CIR

Circor

$44.81

-0.12 (-0.27%)

06:46
06/17/19
06/17
06:46
06/17/19
06:46
Hot Stocks
Breaking Hot Stocks news story on Crane, Circor »

Crane commences tender…

CR

Crane

$79.66

-1.77 (-2.17%)

CIR

Circor

$44.81

-0.12 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$42.75

0.24 (0.56%)

, ARRY

Array BioPharma

$29.59

0.17 (0.58%)

06:45
06/17/19
06/17
06:45
06/17/19
06:45
Hot Stocks
Breaking Hot Stocks news story on Pfizer, Array BioPharma »

Pfizer to acquire Array…

PFE

Pfizer

$42.75

0.24 (0.56%)

ARRY

Array BioPharma

$29.59

0.17 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 16

    Sep

06:45
06/17/19
06/17
06:45
06/17/19
06:45
General news
Stock markets remain cautious ahead of central banks, »

Stock markets remain…

RTLR

Rattler Midstream

$19.21

-0.195 (-1.01%)

, FANG

Diamondback Energy

$98.98

-1.15 (-1.15%)

06:43
06/17/19
06/17
06:43
06/17/19
06:43
Initiation
Rattler Midstream, Diamondback Energy initiated  »

Rattler Midstream…

RTLR

Rattler Midstream

$19.21

-0.195 (-1.01%)

FANG

Diamondback Energy

$98.98

-1.15 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 13

    Sep

RTLR

Rattler Midstream

$19.21

-0.195 (-1.01%)

06:42
06/17/19
06/17
06:42
06/17/19
06:42
Initiation
Rattler Midstream initiated  »

Rattler Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CJ

C&J Energy Services

$10.73

-0.47 (-4.20%)

, FRAC

Keane Group

$6.99

-0.46 (-6.17%)

06:42
06/17/19
06/17
06:42
06/17/19
06:42
Hot Stocks
Breaking Hot Stocks news story on C&J Energy Services, Keane Group »

C&J Energy Services,…

CJ

C&J Energy Services

$10.73

-0.47 (-4.20%)

FRAC

Keane Group

$6.99

-0.46 (-6.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LW

Lamb Weston

$61.67

0.45 (0.74%)

06:40
06/17/19
06/17
06:40
06/17/19
06:40
Initiation
Lamb Weston initiated  »

Lamb Weston initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDYA

Ideaya Biosciences

$10.70

-0.1 (-0.93%)

06:38
06/17/19
06/17
06:38
06/17/19
06:38
Initiation
Ideaya Biosciences initiated  »

Ideaya Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PB

Prosperity Bancshares

$67.23

0.45 (0.67%)

, LTXB

LegacyTexas Financial

$38.22

0.32 (0.84%)

06:38
06/17/19
06/17
06:38
06/17/19
06:38
Hot Stocks
LegacyTexas Financial to merge with Prosperity Bancshares, valued at $2.1B »

Prosperity Bancshares…

PB

Prosperity Bancshares

$67.23

0.45 (0.67%)

LTXB

LegacyTexas Financial

$38.22

0.32 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

AL

Air Lease

$38.85

-0.745 (-1.88%)

, EADSY

Airbus

$0.00

(0.00%)

06:37
06/17/19
06/17
06:37
06/17/19
06:37
Hot Stocks
Air Lease announces lease agreements with Air Caraibes, FrenchBee »

Air Lease (AL) announced…

AL

Air Lease

$38.85

-0.745 (-1.88%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.